# Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)

Source: https://onco.cc/trials/nct06879145/  
OnCo record `nct06879145` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Adebrelimab and SHR-A2102 in bladder & urothelial cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) is a phase 2/3 interventional study registered as NCT06879145 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 840 participants planned, started 2025-04-25 and due to reach its primary completion in 2031-12. Interventions recorded: SHR-A2102；Adebrelimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06879145
- Phase: 2/3
- Setting: A Randomized, Open, Multicenter Phase II/III Clinical Study of SHR-A2102 for Injection Combined With Adebrelimab (SHR-1316) in Perioperative Treatment of Muscular Invasive Bladder Cancer (MIBC)
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 840

## Sources

- ClinicalTrials.gov NCT06879145: https://clinicaltrials.gov/study/NCT06879145

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [SHR-A2102](https://onco.cc/drugs/shr-a2102/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct06879145.json